Compare AEHL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | MBIO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 4.7M |
| IPO Year | 2007 | N/A |
| Metric | AEHL | MBIO |
|---|---|---|
| Price | $3.00 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.0M | 95.8K |
| Earning Date | 12-26-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.99 | N/A |
| 52 Week Low | $1.13 | $0.89 |
| 52 Week High | $11.53 | $21.95 |
| Indicator | AEHL | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 43.45 |
| Support Level | $2.88 | $1.21 |
| Resistance Level | $3.21 | $1.31 |
| Average True Range (ATR) | 0.56 | 0.09 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 66.35 | 21.67 |
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.